ALS 3
Alternative Names: ALS-3Latest Information Update: 05 Jun 2023
Price :
$50 *
At a glance
- Originator Aptorum Group
- Class Antibacterials; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Bacterial infections
Most Recent Events
- 28 Apr 2023 Preclinical trials in Bacterial infections in Hong Kong (unspecified route) prior to April 2023
- 28 Apr 2023 Pharmacodynamics data from a preclinical studies in Bacterial infections released by Aptorum Group
- 30 Aug 2019 Aptorum Group has patent pending for antimicrobial compounds and methods for use Thereof in the US, Europe, Malaysia, Singapore, China, Indonesia, India, Korea and Japan